199865438+On February 28th, the State Administration of Pharmaceutical Products approved "Recombinant human p53 adenovirus injection" to enter the phase I clinical trial. 1999 0 10 The Ministry of Science and Technology listed the project of "recombinant human p53 adenovirus injection" as a leading development project in the field of biotechnology in the 863 Plan.
1999165438+10 In October, Shenzhen listed the project of "recombinant human p53 adenovirus injection" as a key industrialization project in Shenzhen. June 65438, 2000+20001October 7, 2000, the state administration of pharmaceutical products approved "recombinant human p53 adenovirus injection" to enter the second phase clinical trial.
In July, 2000, the project of "recombinant human p53 adenovirus injection" was included in the national technological innovation fund project of small and medium-sized scientific and technological enterprises. 200 1 12 "Recombinant human p53 adenovirus injection" was included in the national key science and technology plan by the Ministry of Science and Technology.
200165438+February Gene Therapy Products Factory was built in Shenzhen Hi-tech Industrial Park. On July 3rd, 2002, "Recombinant human p53 adenovirus injection" was granted a patent in China National Intellectual Property Administration (patent number: ZL 98 1 23346.5).
From August to June, 2002, the State Administration of Pharmaceutical Products agreed to build a new class of drug "recombinant human p53 adenovirus injection workshop".
In 2002, the project "Recombinant human p53 adenovirus injection" was included in the Tenth Five-Year National Science and Technology Plan by the Ministry of Science and Technology.
On1October 22nd, 2002, 165438 obtained the Pharmaceutical Production License issued by Guangdong Drug Administration. On July 9, 2003, Dr. W.French.Anderson, the "father of gene therapy", was hired as a consultant of Cybertron.
In July 2003, the restructuring of the new Spino Company was completed, with a registered capital of 4810.9 million yuan.
On June 65438+1October 65438+June 2003, "Recombinant human p53 adenovirus injection" (registered trademark: Jinshengyou) obtained the first-class new drug certificate of biological products approved and issued by the US Food and Drug Administration. 065438+2004120 October "Recombinant human p53 adenovirus injection" (registered trade name: Jin Shengzai) obtained the production approval issued by the US Food and Drug Administration.
In March 2004, 1 1 "Recombinant human p53 adenovirus injection" (registered trademark: Jinsheng) workshop obtained the GMP certificate issued by the US Food and Drug Administration.
On June 10, 2004, the foundation stone of Spino gene therapy drug production base was laid in Shenzhen High-tech Industrial Park.
From June 5-438, 2004 to October 22, 2004/kloc-0, our company's project "The relationship between p53 gene variation and clinical efficacy in repeated clinical trials" was officially approved by the Ministry of Science and Technology and included in the national key basic research development plan (973 plan). In June 2006, he won the "Global Enterprise Innovation Award", which was personally presented by Singapore President S.R.Nathan.
From June 5, 2006 to 2006 10, Benda Pharmaceutical Co., Ltd. acquired about 68% of the company's equity and reorganized the board of directors with Mr. Peng. On June 22nd, 2007, 65438+ signed the project of "Sino-Japanese cooperative research and development of AIDS gene therapy vaccine".
On May 25th, 2007, Spino was awarded two new invention patents by People's Republic of China (PRC) and China National Intellectual Property Administration.
On June 25, 2007, 20 enterprises including Shenzhen Saibainuo Gene Technology Co., Ltd. won the honorary title of "Shenzhen Intellectual Property Advantage Enterprise".
From June 5438 to 10, 2007, Lindsey Barsoom, a senior reporter from British TV 4, visited Cybertron, the Oncology Department of Shenzhen Second Hospital and the Gene Therapy Center of Beijing Haidian Hospital with the topic of "rebirth today". On June 22, 2008, 65438, the project of "Sino-Japanese cooperation in research and development of AIDS gene therapy vaccine" was signed. the year of 2008
In June 5438+February 65438+May 2008, the company's scientific and technological expert committee was established. Academician Zeng Yixin, Academician Wu Zuze, Academician Sun Yan, Academician Wei Yuquan and Professor Huang Wenlin, authoritative experts in the field of gene therapy in China, were appointed as the first members of the company's science and technology expert committee, and Academician Zeng Yixin was appointed as the chairman. Wu Zuze, a senior academician of Chinese Academy of Sciences, sent a special message to Sibeno Company: Establish a strategic platform for science and technology and build a characteristic gene industry.
On June 5438+February, 2008 1 1, the company's president Xu was selected as one of the "Top 100 Entrepreneurs in Shenzhen" and won the title of "100 Outstanding Entrepreneur in Shenzhen in the Thirty Years of China's Reform and Opening-up".